Loading clinical trials...
Loading clinical trials...
A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma
Conditions
Interventions
bevacizumab
carboplatin
+1 more
Locations
1
United States
Stanford University School of Medicine
Stanford, California, United States
Start Date
February 1, 2009
Primary Completion Date
December 31, 2017
Completion Date
December 31, 2017
Last Updated
January 14, 2025
NCT07070466
NCT07447050
NCT07371663
NCT06447064
NCT07212933
NCT06732856
Lead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions